Nuformix plc (LON:NFX – Get Free Report)’s stock price fell 15% during mid-day trading on Tuesday. The stock traded as low as GBX 0.09 and last traded at GBX 0.10. 36,537,223 shares were traded during trading, an increase of 26% from the average session volume of 29,015,109 shares. The stock had previously closed at GBX 0.11.
Nuformix Stock Down 15.0%
The firm has a market capitalization of £2.51 million, a PE ratio of -3.28 and a beta of 1.53. The company has a 50-day moving average of GBX 0.15 and a 200 day moving average of GBX 0.16.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.
Featured Stories
- Five stocks we like better than Nuformix
- Meta Platforms’ AI Comeback Faces an Earnings Test—And a $10 Billion Charge
- IonQ’s Bold Expansion Could Leave Shareholders Paying the Price
- Powering Up: Applied Digital Execs Buy $6.7M in Stock
- Chip Stocks Are Sliding—Why Is Smart Money Buying?
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
